Biomotion Sciences Warrant
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for … Read more
Biomotion Sciences Warrant (SLXNW) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.407x
Based on the latest financial reports, Biomotion Sciences Warrant (SLXNW) has a cash flow conversion efficiency ratio of -0.407x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.84 Million) by net assets ($6.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biomotion Sciences Warrant - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Biomotion Sciences Warrant's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Biomotion Sciences Warrant Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biomotion Sciences Warrant ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Temir Corp
PINK:TMRR
|
-0.013x |
|
Picton Property Income Ltd
LSE:PCTN
|
0.018x |
|
VCI Global Limited Ordinary Share
NASDAQ:VCIG
|
0.154x |
|
RAKUTEN
BE:RAK
|
0.458x |
|
Truen Co. Ltd.
KO:417790
|
N/A |
|
Solidwizard Technology Co., Ltd.
TWO:8416
|
N/A |
|
STANDARD SUPPLY NK -10
F:D6Z
|
N/A |
|
Filtronic
LSE:FTC
|
0.330x |
Annual Cash Flow Conversion Efficiency for Biomotion Sciences Warrant (2020–2024)
The table below shows the annual cash flow conversion efficiency of Biomotion Sciences Warrant from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-3.99 Million | $-8.40 Million | 2.105x | +460.29% |
| 2023-12-31 | $-12.06 Million | $-4.53 Million | 0.376x | -20.26% |
| 2022-12-31 | $-7.08 Million | $-3.33 Million | 0.471x | +3946.78% |
| 2021-12-31 | $114.91 Million | $-1.41 Million | -0.012x | -102.78% |
| 2020-12-31 | $-169.99K | $-75.00K | 0.441x | -- |